Mechanisms of echinocandin antifungal drug resistance

被引:212
作者
Perlin, David S. [1 ]
机构
[1] Rutgers Biomed & Hlth Sci, New Jersey Med Sch, Publ Hlth Res Inst, Newark, NJ 07103 USA
来源
ANTIMICROBIAL THERAPEUTICS REVIEWS | 2015年 / 1354卷
关键词
echinocandin; caspofungin; micafungin; FKS; glucan synthase; chitin synthase; EPIDEMIOLOGIC CUTOFF VALUES; STEM-CELL TRANSPLANTATION; IN-VITRO ACTIVITY; CANDIDA-GLABRATA INFECTION; INVASIVE FUNGAL-INFECTIONS; CLSI CLINICAL BREAKPOINTS; BLOOD-STREAM INFECTIONS; SACCHAROMYCES-CEREVISIAE; FKS MUTATIONS; AMPHOTERICIN-B;
D O I
10.1111/nyas.12831
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Fungal infections due to Candida and Aspergillus species cause extensive morbidity and mortality, especially among immunosuppressed patients, and antifungal therapy is critical to patient management. Yet only a few drug classes are available to treat invasive fungal diseases, and this problem is compounded by the emergence of antifungal resistance. Echinocandin drugs are the preferred choice to treat candidiasis. They are the first cell wall active agents and target the fungal-specific enzyme glucan synthase, which catalyzes the biosynthesis of beta-1,3-glucan, a key cell wall polymer. Therapeutic failures occur rarely among common Candida species, with the exception of Candida glabrata, which is frequently multidrug resistant. Echinocandin resistance in susceptible species is always acquired during therapy. The mechanism of resistance involves amino acid changes in hot-spot regions of Fks subunits of glucan synthase, which decrease the sensitivity of the enzyme to drug. Cellular stress response pathways lead to drug adaptation, which promotes the formation of resistant fks strains. Clinical factors promoting echinocandin resistance include empiric therapy, prophylaxis, gastrointestinal reservoirs, and intra-abdominal infections. A better understanding of the echinocandin-resistance mechanism, along with cellular and clinical factors promoting resistance, will facilitate more effective strategies to overcome and prevent echinocandin resistance.
引用
收藏
页码:1 / 11
页数:11
相关论文
共 131 条
[1]   Increasing Echinocandin Resistance in Candida glabrata: Clinical Failure Correlates With Presence of FKS Mutations and Elevated Minimum Inhibitory Concentrations [J].
Alexander, Barbara D. ;
Johnson, Melissa D. ;
Pfeiffer, Christopher D. ;
Jimenez-Ortigosa, Cristina ;
Catania, Jelena ;
Booker, Rachel ;
Castanheira, Mariana ;
Messer, Shawn A. ;
Perlin, David S. ;
Pfaller, Michael A. .
CLINICAL INFECTIOUS DISEASES, 2013, 56 (12) :1724-1732
[2]   Echinocandin resistance: an emerging clinical problem? [J].
Arendrup, Maiken C. ;
Perlin, David S. .
CURRENT OPINION IN INFECTIOUS DISEASES, 2014, 27 (06) :484-492
[3]   Breakpoints for antifungal agents: An update from EUCAST focussing on echinocandins against Candida spp. and triazoles against Aspergillus spp. [J].
Arendrup, Maiken C. ;
Cuenca-Estrella, Manuel ;
Lass-Floerl, Cornelia ;
Hope, William W. .
DRUG RESISTANCE UPDATES, 2013, 16 (06) :81-95
[4]   Differential In Vivo Activities of Anidulafungin, Caspofungin, and Micafungin against Candida glabrata Isolates with and without FKS Resistance Mutations [J].
Arendrup, Maiken Cavling ;
Perlin, David S. ;
Jensen, Rasmus Hare ;
Howard, Susan Julie ;
Goodwin, Joanne ;
Hope, William .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2012, 56 (05) :2435-2442
[5]   Antifungal combinations against Candida albicans biofilms in vitro [J].
Bachmann, SP ;
Ramage, G ;
VandeWalle, K ;
Patterson, TF ;
Wickes, BL ;
López-Ribot, JL .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (11) :3657-3659
[6]   In vitro activity of caspofungin (MK-0991) against Candida albicans clinical isolates displaying different mechanisms of azole resistance [J].
Bachmann, SP ;
Patterson, TF ;
López-Ribot, JL .
JOURNAL OF CLINICAL MICROBIOLOGY, 2002, 40 (06) :2228-2230
[7]   Comparison of the fungicidal activities of caspofungin and amphotericin B against Candida glabrata [J].
Barchiesi, F ;
Spreghini, E ;
Tomassetti, S ;
Arzeni, D ;
Giannini, D ;
Scalise, G .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2005, 49 (12) :4989-4992
[8]   Fitness and Virulence Costs of Candida albicans FKS1 Hot Spot Mutations Associated With Echinocandin Resistance [J].
Ben-Ami, Ronen ;
Garcia-Effron, Guillermo ;
Lewis, Russell E. ;
Gamarra, Soledad ;
Leventakos, Konstantinos ;
Perlin, David S. ;
Kontoyiannis, Dimitrios P. .
JOURNAL OF INFECTIOUS DISEASES, 2011, 204 (04) :626-635
[9]   FKS Mutant Candida glabrata: Risk Factors and Outcomes in Patients With Candidemia [J].
Beyda, Nicholas D. ;
John, Julie ;
Kilic, Abdullah ;
Alam, Mohammad J. ;
Lasco, Todd M. ;
Garey, Kevin W. .
CLINICAL INFECTIOUS DISEASES, 2014, 59 (06) :819-825
[10]   Breakthrough Candidemia Due to Multidrug-Resistant Candida glabrata during Prophylaxis with a Low Dose of Micafungin [J].
Bizerra, Fernando Cesar ;
Jimenez-Ortigosa, Cristina ;
Souza, Ana Carolina R. ;
Breda, Giovanni Luis ;
Queiroz-Telles, Flavio ;
Perlin, David S. ;
Colombo, Arnaldo L. .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2014, 58 (04) :2438-2440